Atossa Genetics rallies on hopes for ForeCYTE

|About: Atossa Genetics, Inc. (ATOS)|By:, SA News Editor

Shares of Atossa Genetics (ATOS) rally 20% premarket as the company submits a premarket 510(k) notification to the FDA for the ForeCYTE Breast Aspirator.

The company notes that the regulator usually makes a decision within 90 days.

The product will be re-launched upon clearance. (PR)

For reference on this story, see here and here.